Pneumococcal vaccine conjugate 11-valent - GlaxoSmithKline

Drug Profile

Pneumococcal vaccine conjugate 11-valent - GlaxoSmithKline

Alternative Names: 11-Pn-CV; 11Pn-PD; GSK 513026; Pneumococcal 11-valent vaccine conjugate - GlaxoSmithKline

Latest Information Update: 22 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pneumococcal infections

Most Recent Events

  • 31 Dec 2011 Discontinued during 2011 - Phase-III for Pneumococcal infections (in children, prevention) in Slovakia (IM)
  • 31 Dec 2011 Discontinued during 2011 - Phase-III for Pneumococcal infections (in infants, prevention) in Czech Republic and Slovakia (IM)
  • 31 Dec 2011 Discontinued - Phase-II for Pneumococcal infections (prevention in infants) in Germany (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top